(Q46965621)

26 December 2017

title

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa (English)

1 reference

26 December 2017

1 reference

8

Carl E Frasch

1 reference

26 December 2017

author name string

Che-Hung Lee

1

1 reference

26 December 2017

Wen-Chun Kuo

2

1 reference

26 December 2017

Suresh Beri

3

1 reference

26 December 2017

Subash Kapre

4

1 reference

26 December 2017

Jayant S Joshi

5

1 reference

26 December 2017

Nancy Bouveret

6

1 reference

26 December 2017

F Marc LaForce

7

1 reference

26 December 2017

language of work or name

English

0 references

publication date

6 December 2008

1 reference

26 December 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

26 December 2017

volume

27

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

726-732

1 reference

26 December 2017

Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

The duration of the antibody response to meningococcal vaccination in an African village

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Clinical practice. Prevention of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Prospects for vaccine prevention of meningococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

The Meningitis Vaccine Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Re.: Trinitrophenyl-protein conjugates are more complex than it is currently thought

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide--protein conjugate vaccine is decreased by admixture of high doses of free saccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.065

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.11.065

1 reference

26 December 2017

1 reference

26 December 2017